EX-99.1 2 tm2323120d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates

1H 2023 Revenue Growth of 16% at CER to $180.8M

Raising FY 2023 Galafold® Revenue Growth Guidance to 14%-18% at CER

EU Launch of Pombiliti® + Opfolda® Underway; U.S. and U.K. Approvals Expected 3Q 2023

Reducing 2023 Non-GAAP Operating Expense Guidance to $330M-$350M

Non-GAAP Profitability Projected in 2H 2023

Conference Call and Webcast Today at 8:30 a.m. ET

PHILADELPHIA, PA, Aug. 8, 2023 – Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the second quarter ended June 30, 2023.

Bradley Campbell, President and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “Amicus has made tremendous progress through the first half of 2023, highlighted by the strong growth of Galafold and the regulatory approval of Pombiliti and Opfolda in the EU. We are confident in our trajectory towards delivering on our core objectives this year, including the continued growth of Galafold and the anticipated approvals of Pombiliti and Opfolda in the U.S. and U.K. this quarter. I am also very pleased to share we have revised our revenue guidance upwards and are reducing operating expense guidance for the year further supporting our path to non-GAAP profitability. Amicus is well positioned to deliver sustainable value for our shareholders while advancing our mission to deliver great medicines for people living with rare diseases.”

Corporate Highlights:

| · | Global revenue in the second quarter 2023 was $94.5 million. Second quarter revenue represented a year-over-year increase of 17% from total revenue of $80.7 million in the second quarter 2022. Second quarter performance reflected a strong operational revenue growth of 17% measured at constant exchange rates (CER)1 and a negligible currency impact of $0.2 million, or 0%.

| · | Global revenue in the first half 2023 was $180.8 million. First half revenue represented a year-over-year increase of 13% from total revenue of $159.4 million in the first half 2022. First half performance reflected strong operational revenue growth of 16% measured at constant exchange rates (CER)1 and a negative currency impact of $4.1 million, or 3%.

|  | Three Months Ended June 30, |  |  | Year over Year % Growth |  |  | Six Months Ended June 30, |  |  | Year over Year % Growth |
(in thousands) |  | 2023 |  |  | 2022 |  |  | As Reported |  |  | at CER1 |  |  | 2023 |  |  | 2022 |  |  | As Reported |  |  | at CER1 |
Net Product Revenues |  | $ | 94,503 |  |  | $ | 80,731 |  |  |  | 17 | % |  |  | 17 | % |  | $ | 180,773 |  |  | $ | 159,446 |  |  |  | 13 | % |  |  | 16 | %

| · | Given strong operational performance in the first half of 2023, the Company now anticipates Galafold® revenue growth of 14-18% at CER1 for the full-year 2023. Growth is expected to be driven by continued underlying demand from both switch and treatment-naïve patients, geographic expansion, label extensions, continued diagnosis of new Fabry patients, and commercial execution across all major markets, including the U.S., EU, U.K., and Japan.

| · | Commercial Launch of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) underway in the EU. In the EU, the European Commission granted full approval of Pombiliti + Opfolda for the treatment of adults with late-onset Pompe disease (LOPD). The Company has initiated the commercial launch of Pombiliti + Opfolda in Germany and reimbursement discussions with healthcare authorities in additional European countries are underway.

1

| · | U.S. and U.K. regulatory reviews of AT-GAA remain on-track. The Company continues to expect regulatory approvals of AT-GAA in both the U.S. and U.K. in the third quarter of 2023.

| · | Galafold U.S. intellectual property estate further strengthened following the issuance of multiple new patents in 2023. Galafold is protected by orphan drug regulatory exclusivities and a broad U.S. intellectual property portfolio of 53 orange book-listed patents, including 9 composition of matter patents, 37 of which provide protection through 2038 and beyond.

| · | Full-year 2023 non-GAAP operating expense guidance reduced to $330 million to $350 million, driven by prudent expense management while investing in AT-GAA manufacturing and launch activities.

| · | Based on the current operating plan and the timing of AT-GAA approvals, the Company is on-track to achieve non-GAAP profitability2 in the second half of 2023.

| · | Amicus announces retirement of Chief Financial Officer, Daphne Quimi. After 15 years of distinguished leadership at Amicus, Daphne Quimi has decided to retire. Ms. Quimi will remain in her role as CFO until her successor is appointed and will remain with Amicus through the end of the year in order to support a smooth transition.

Second Quarter 2023 Financial Results

| · | Total revenue in the second quarter 2023 was $94.5 million, a year-over-year increase of 17% from total revenue of $80.7 million in the second quarter 2022. On a constant currency basis, second quarter 2023 total revenue growth was 17%. Currency impact on reported revenue in the second quarter of 2023 represented a negligible amount of $0.2 million, or 0%.
| · | Total GAAP operating expenses of $104.2 million for the second quarter 2023 decreased as compared to $133.1 million for the second quarter 2022.
| · | Total non-GAAP operating expenses of $84.0 million for the second quarter 2023 decreased as compared to $119.2 million for the second quarter 2022, primarily reflecting decreased program spend.3
| · | Net loss was $43.2 million, or $0.15 per share in the second quarter 2023, and was reduced compared to a net loss of $62.2 million, or $0.21 per share, for the second quarter 2022.
| · | Cash, cash equivalents, and marketable securities totaled $265.6 million at June 30, 2023, compared to $293.6 million at December 31, 2022.

2023 Financial Guidance

| · | For the full-year 2023, the Company now anticipates total Galafold revenue growth between 14 and 18% at CER1 driven by several factors including continued strong underlying demand from both switch and treatment-naïve patients further geographic expansion and label extensions, the continued diagnosis of new Fabry patients and commercial execution across all major markets, including the U.S., EU, U.K., and Japan.
| · | Amicus is reducing its non-GAAP operating expense guidance for the full-year 2023 to $330 million to $350 million, driven by prudent expense management offset by continued investment in Galafold, AT-GAA clinical studies, non-recurring costs for manufacturing as well as global launch activities4.
| · | The Company is on-track to achieve non-GAAP profitability2 in the second half of 2023.

Amicus is focused on the following five key strategic priorities in 2023:

| · | Sustain double-digit Galafold revenue growth (14-18% at CER 1)
| · | Secure EMA, MHRA and FDA approvals for Pombiliti + Opfolda
| · | Initiate successful global launches of Pombiliti + Opfolda
| · | Advance next generation pipeline programs (Fabry GTx, Fabry Next-Generation Chaperone, Pompe GTx)
| · | Maintain strong financial position on path to profitability

1 In order to illustrate underlying performance, Amicus discusses its results in terms of constant exchange rate (CER) growth. This represents growth calculated as if the exchange rates had remained unchanged from those used in the comparative period. Full-year 2023 Galafold revenue guidance utilizes the actual exchange rates at December 31, 2022.

2 Based on projections of Amicus’ non-GAAP Net Income under current operating plans, which includes successful AT-GAA regulatory approvals and continued Galafold growth. Amicus defines non-GAAP Net Income as GAAP Net Income excluding the impact of share-based compensation expense, changes in fair value of contingent consideration, loss on impairment of assets, depreciation and amortization, acquisition related income (expense), loss on extinguishment of debt, restructuring charges and income taxes.

3 Full reconciliation of GAAP results to the Company’s non-GAAP adjusted measures for all reporting periods appear in the tables to this press release.

4 A reconciliation of the differences between the non-GAAP expectation and the corresponding GAAP measure is not available without unreasonable effort due to high variability, complexity, and low visibility as to the items that would be excluded from the GAAP measure.

2

Conference Call and Webcast

Amicus Therapeutics will host a conference call and audio webcast today, August 8, 2023, at 8:30 a.m. ET to discuss the second quarter 2023 financial results and corporate updates. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event.

A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com. Web participants are encouraged to register on the website 15 minutes prior to the start of the call. An archived webcast and accompanying slides will be available on the Company's website shortly after the conclusion of the live event.

About Galafold

Galafold® (migalastat) 123 mg capsules is an oral pharmacological chaperone of alpha-Galactosidase A (alpha-Gal A) for the treatment of Fabry disease in adults who have amenable galactosidase alpha gene (GLA) variants. In these patients, Galafold works by stabilizing the body’s own dysfunctional enzyme so that it can clear the accumulation of disease substrate. Globally, Amicus Therapeutics estimates that approximately 35 to 50 percent of Fabry patients may have amenable GLA variants, though amenability rates within this range vary by geography. Galafold is approved in more than 40 countries around the world, including the U.S., EU, U.K., and Japan.

U.S. INDICATIONS AND USAGE

Galafold is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.

This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

U.S. IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

The most common adverse reactions reported with Galafold (≥10%) were headache, nasopharyngitis, urinary tract infection, nausea and pyrexia.

USE IN SPECIFIC POPULATIONS

There is insufficient clinical data on Galafold use in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. Advise women of the potential risk to a fetus.

It is not known if Galafold is present in human milk. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Galafold and any potential adverse effects on the breastfed child from Galafold or from the underlying maternal condition.

Galafold is not recommended for use in patients with severe renal impairment or end-stage renal disease requiring dialysis.

The safety and effectiveness of Galafold have not been established in pediatric patients.

To report Suspected Adverse Reactions, contact Amicus Therapeutics at 1-877-4AMICUS or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For additional information about Galafold, including the full U.S. Prescribing Information, please visit https://www.amicusrx.com/pi/Galafold.pdf.

EU Therapeutic Indication

Galafold® (migalastat) is indicated for long-term treatment of adults and adolescents aged 12 years and older with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) and who have an amenable mutation.

EU Important Safety Information

Treatment with Galafold should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of Fabry disease. Galafold is not intended for concomitant use with enzyme replacement therapy.

The safety and efficacy of Galafold in children aged less than 12 years have not been established. No data are available.

Galafold is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients listed in the Summary of Product Characteristics (SmPC).

Galafold 123 mg capsules are not for children (≥12 years) weighing less than 45 kg.

3

It is advised to periodically monitor renal function, echocardiographic parameters and biochemical markers (every 6 months) in patients initiated on or switched to Galafold. In case of meaningful clinical deterioration, further clinical evaluation or discontinuation of treatment with Galafold should be considered.

Galafold is not indicated for use in patients with non-amenable mutations.

Galafold is not recommended for use in patients with severe renal insufficiency, defined as estimated GRF less than 30 mL/min/1.73m2.

Food and caffeine should not be consumed at least 2 hours before and 2 hours after taking Galafold to give a minimum 4 hours fast.

Galafold is not recommended in women of childbearing potential not using contraception. Galafold is not recommended during pregnancy. It is not known whether Galafold is secreted in human milk.

The most common adverse reaction reported was headache, which was experienced by approximately 10% of patients who received Galafold. For a complete list of adverse reactions, please review the SmPC.

OVERDOSE: General medical care is recommended in the case of Galafold overdose.

For complete information please see the EU SmPC available at https://www.ema.europa.eu/en/medicines/human/EPAR/galafold

About Pombiliti® + Opfolda®

Pombiliti + Opfolda, is a two-component therapy that consists of cipaglucosidase alfa, a bis-M6P-enriched rhGAA that facilitates high-affinity uptake through the M6P receptor while retaining its capacity for processing into the most active form of the enzyme, and the oral enzyme stabilizer, miglustat, that’s designed to reduce loss of enzyme activity in the blood. In clinical studies, Pombiliti + Opfolda was associated with demonstrated improvements in both musculoskeletal and respiratory measures.

Important Safety Information

Pombiliti (cipaglucosidase alfa) Important Safety Information

Posology and Method of Administration: Pombiliti must be used in combination with miglustat 65 mg hard capsules. The recommended dose of Pombiliti is 20 mg/kg of body weight every other week. The Pombiliti infusion should start 1 hour after taking miglustat capsules. Paediatric population: The safety and efficacy of Pombiliti in combination with miglustat therapy in paediatric patients less than 18 years old have not yet been established. No data are available. Contraindications: Life-threatening hypersensitivity to the active substance, or to any of the excipients. Contraindication to miglustat. Anaphylaxis and infusion-associated reactions (IARs): Serious anaphylaxis and IARs have occurred in some patients during infusion and following infusion with Pombiliti. Premedication with oral antihistamine, antipyretics, and/or corticosteroids may be administered to assist with signs and symptoms related to IARs experienced with prior enzyme replacement therapy (ERT) treatment. Reduction of the infusion rate, temporary interruption of the infusion, symptomatic treatment with oral antihistamine, or antipyretics, and appropriate resuscitation measures should be considered to manage serious IARs. If anaphylaxis or severe allergic reactions occur, infusion should be immediately paused, and appropriate medical treatment should be initiated. The current medical standards for emergency treatment of anaphylactic reactions are to be observed and cardiopulmonary resuscitation equipment should be readily available. The risks and benefits of re-administering Pombiliti following anaphylaxis or severe allergic reaction should be carefully considered, and appropriate resuscitation measures made available. Risk of acute cardiorespiratory failure in susceptible patients: Patients with acute underlying respiratory illness or compromised cardiac and/or respiratory function may be at risk of serious exacerbation of their cardiac or respiratory compromise during infusions. Appropriate medical support and monitoring measures should be readily available during Pombiliti infusion. Immune complex-related reactions: Immune complex-related reactions have been reported with other ERTs in patients who had high IgG antibody titres, including severe cutaneous reactions and nephrotic syndrome. If immune complex-related reactions occur, discontinuation of the administration of Pombiliti should be considered and appropriate medical treatment should be initiated. The risks and benefits of re-administering Pombiliti following an immune complex-related reaction should be reconsidered for each individual patient. Contraception in females: Reliable contraceptive measures must be used by women of childbearing potential during treatment with Pombiliti in combination with miglustat, and for 4 weeks after discontinuing treatment. Pregnancy: Pombiliti in combination with miglustat therapy is not recommended during pregnancy. Breast feeding: It is not known if Pombiliti and miglustat are secreted in human breast milk. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Pombiliti in combination with miglustat therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. Summary of the safety profile: The most commonly reported adverse reactions only attributable to Pombiliti were chills (4.0%), dizziness (2.6%), flushing (2.0%), somnolence (2.0%), chest discomfort (1.3%), cough, (1.3%), infusion site swelling (1.3%), and pain (1.3%). Reported serious adverse reactions only attributable to Pombiliti were urticaria (2.0%), anaphylaxis (1.3%), pyrexia (0.7%), presyncope (0.7%), dyspnoea (0.7%), pharyngeal oedema (0.7%), wheezing (0.7%), and hypotension (0.7%). Refer to SmPC for full list.

4

Opfolda (miglustat) 65 mg hard capsules Important Safety Information

Posology and Method of Administration: Opfolda must be used in combination with Pombiliti. The recommended dose is to be taken orally every other week and is based on body weight. Opfolda should be taken approximately 1 hour but no more than 3 hours before the start of the Pombiliti infusion. Paediatric population: The safety and efficacy of Opfolda in combination with Pombiliti therapy in paediatric patients less than 18 years old have not yet been established. No data are available. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Contraindication to cipaglucosidase alfa. Food Interaction: Patients should fast for 2 hours before and 2 hours after taking Opfolda. Contraception in females: Reliable contraceptive measures must be used by women of childbearing potential during treatment with Opfolda in combination with Pombiliti, and for 4 weeks after discontinuing treatment. Pregnancy: Opfolda crosses the placenta. Opfolda in combination with Pombiliti therapy is not recommended during pregnancy. Breast feeding: It is not known if Opfolda and Pombiliti are secreted in human breast milk. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Opfolda in combination with Pombiliti therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman. Summary of the safety profile: The most commonly reported adverse reaction only attributable to Opfolda 65 mg was constipation (1.3%). Refer to SmPC for full list.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.

Non-GAAP Financial Measures

In addition to financial information prepared in accordance with U.S. GAAP, this press release also contains adjusted financial measures that we believe provide investors and management with supplemental information relating to operating performance and trends that facilitate comparisons between periods and with respect to projected information. These adjusted financial measures are non-GAAP measures and should be considered in addition to, but not as a substitute for, the information prepared in accordance with U.S. GAAP. We typically exclude certain GAAP items that management does not believe affect our basic operations and that do not meet the GAAP definition of unusual or non-recurring items. Other companies may define these measures in different ways. When we provide our expectation for non-GAAP operating expenses on a forward-looking basis, a reconciliation of the differences between the non-GAAP expectation and the corresponding GAAP measure generally is not available without unreasonable effort due to potentially high variability, complexity and low visibility as to the items that would be excluded from the GAAP measure in the relevant future period, such as unusual gains or losses. The variability of the excluded items may have a significant, and potentially unpredictable, impact on our future GAAP results.

5

Forward Looking Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities, including as they are impacted by COVID-19 related disruption, are based on current information. The potential impact on operations from the COVID-19 pandemic is inherently unknown and cannot be predicted with confidence and may cause actual results and performance to differ materially from the statements in this release, including without limitation, because of the impact on general political and economic conditions, including as a result of efforts by governmental authorities to mitigate COVID-19, such as travel bans, shelter in place orders and third-party business closures and resource allocations, manufacturing and supply chain disruptions and limitations on patient access to commercial or clinical product. In addition to the impact of the COVID-19 pandemic, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation: the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities, including the FDA, EMA, MHRA, and PMDA, may not grant or may delay approval for our product candidates; the potential that required regulatory inspections may be delayed or not be successful and delay or prevent product approval; the potential that we may not be successful in commercializing Galafold in Europe, Japan, the US and other geographies or AT-GAA if and when approved; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we may not be able to manufacture or supply sufficient clinical or commercial products; and the potential that we will need additional funding to complete all of our studies and manufacturing. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. Statements regarding corporate financial guidance and financial goals and the attainment of such goals. With respect to statements regarding projections of the Company's revenue and cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2022, and on Form 10-Q for the quarter ended June 30, 2023, to be filed today. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

CONTACT:

Investors:

Amicus Therapeutics

Andrew Faughnan

Vice President, Investor Relations

afaughnan@amicusrx.com

(609) 662-3809

Media:

Amicus Therapeutics

Diana Moore

Head of Global Corporate Communications

dmoore@amicusrx.com

(609) 662-5079

FOLD-G

6

TABLE 1

Amicus Therapeutics, Inc.

Consolidated Statements of Operations

(Unaudited)

(in thousands, except share and per share amounts)

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Net product sales |  | $ | 94,503 |  |  | $ | 80,731 |  |  | $ | 180,773 |  |  | $ | 159,446 |
Cost of goods sold |  |  | 9,114 |  |  |  | 8,197 |  |  |  | 16,056 |  |  |  | 15,779 |
Gross profit |  |  | 85,389 |  |  |  | 72,534 |  |  |  | 164,717 |  |  |  | 143,667 |
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  | 35,149 |  |  |  | 78,319 |  |  |  | 76,648 |  |  |  | 159,836 |
Selling, general, and administrative |  |  | 65,423 |  |  |  | 53,379 |  |  |  | 139,380 |  |  |  | 111,495 |
Changes in fair value of contingent consideration payable |  |  | 337 |  |  |  | 115 |  |  |  | 588 |  |  |  | (1,073 | )
Loss on impairment of assets |  |  | 1,134 |  |  |  | — |  |  |  | 1,134 |  |  |  | 6,616 |
Depreciation and amortization |  |  | 2,206 |  |  |  | 1,334 |  |  |  | 3,463 |  |  |  | 2,745 |
Total operating expenses |  |  | 104,249 |  |  |  | 133,147 |  |  |  | 221,213 |  |  |  | 279,619 |
Loss from operations |  |  | (18,860 | ) |  |  | (60,613 | ) |  |  | (56,496 | ) |  |  | (135,952 | )
Other (expense) income: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  | 1,737 |  |  |  | 356 |  |  |  | 3,936 |  |  |  | 489 |
Interest expense |  |  | (12,492 | ) |  |  | (8,257 | ) |  |  | (24,336 | ) |  |  | (16,404 | )
Other (expense) income |  |  | (10,902 | ) |  |  | 7,268 |  |  |  | (16,840 | ) |  |  | 9,170 |
Loss before income tax |  |  | (40,517 | ) |  |  | (61,246 | ) |  |  | (93,736 | ) |  |  | (142,697 | )
Income tax expense |  |  | (2,715 | ) |  |  | (911 | ) |  |  | (2,428 | ) |  |  | (4,720 | )
Net loss attributable to common stockholders |  | $ | (43,232 | ) |  | $ | (62,157 | ) |  | $ | (96,164 | ) |  | $ | (147,417 | )
Net loss attributable to common stockholders per common share — basic and diluted |  | $ | (0.15 | ) |  | $ | (0.21 | ) |  | $ | (0.33 | ) |  | $ | (0.51 | )
Weighted-average common shares outstanding — basic and diluted |  |  | 292,797,002 |  |  |  | 291,970,562 |  |  |  | 292,071,201 |  |  |  | 288,646,587 |

7

TABLE 2

Amicus Therapeutics, Inc.

Consolidated Balance Sheets

(Unaudited)

(in thousands, except share and per share amounts)

|  | June 30, 2023 |  |  | December 31, 2022 |
Assets |  |  |  |  |  |  |  |
Current assets: |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 211,307 |  |  | $ | 148,813 |
Investments in marketable securities |  |  | 54,319 |  |  |  | 144,782 |
Accounts receivable |  |  | 63,716 |  |  |  | 66,196 |
Inventories |  |  | 51,381 |  |  |  | 23,816 |
Prepaid expenses and other current assets |  |  | 52,099 |  |  |  | 40,209 |
Total current assets |  |  | 432,822 |  |  |  | 423,816 |
Operating lease right-of-use assets, net |  |  | 28,042 |  |  |  | 29,534 |
Property and equipment, less accumulated depreciation of $24,060 and $22,281 at June 30, 2023 and December 31, 2022, respectively |  |  | 30,238 |  |  |  | 30,778 |
Intangible asset, less accumulated depreciation of $855 and $0 at June 30, 2023 and December 31, 2022, respectively |  |  | 22,145 |  |  |  | 23,000 |
Goodwill |  |  | 197,797 |  |  |  | 197,797 |
Other non-current assets |  |  | 19,049 |  |  |  | 19,242 |
Total Assets |  | $ | 730,093 |  |  | $ | 724,167 |
Liabilities and Stockholders' Equity |  |  |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |  |  |
Accounts payable |  | $ | 13,522 |  |  | $ | 15,413 |
Accrued expenses and other current liabilities |  |  | 124,868 |  |  |  | 93,636 |
Contingent consideration payable |  |  | 13,005 |  |  |  | 21,417 |
Operating lease liabilities |  |  | 7,840 |  |  |  | 8,552 |
Total current liabilities |  |  | 159,235 |  |  |  | 139,018 |
Long-term debt |  |  | 393,350 |  |  |  | 391,990 |
Operating lease liabilities |  |  | 50,976 |  |  |  | 51,578 |
Deferred reimbursements |  |  | 5,906 |  |  |  | 4,656 |
Deferred income taxes |  |  | — |  |  |  | 4,939 |
Other non-current liabilities |  |  | 9,045 |  |  |  | 8,939 |
Total liabilities |  |  | 618,512 |  |  |  | 601,120 |
Commitments and contingencies |  |  |  |  |  |  |  |
Stockholders' equity: |  |  |  |  |  |  |  |
Common stock, $0.01 par value, 500,000,000 shares authorized, 286,992,923 and 281,108,273 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively |  |  | 2,856 |  |  |  | 2,815 |
Additional paid-in capital |  |  | 2,733,148 |  |  |  | 2,664,744 |
Accumulated other comprehensive gain (loss): |  |  |  |  |  |  |  |
Foreign currency translation adjustment |  |  | 4,337 |  |  |  | (11,989 | )
Unrealized loss on available-for-sale securities |  |  | (177 | ) |  |  | (116 | )
Warrants |  |  | 71 |  |  |  | 83 |
Accumulated deficit |  |  | (2,628,654 | ) |  |  | (2,532,490 | )
Total stockholders' equity |  |  | 111,581 |  |  |  | 123,047 |
Total Liabilities and Stockholders' Equity |  | $ | 730,093 |  |  | $ | 724,167 |

8

TABLE 3

Amicus Therapeutics, Inc.

Reconciliation of Non-GAAP Financial Measures

(in thousands)

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Total operating expenses - as reported GAAP |  | $ | 104,249 |  |  | $ | 133,147 |  |  | $ | 221,213 |  |  | $ | 279,619 |
Research and development: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock-based compensation |  |  | 4,117 |  |  |  | 4,379 |  |  |  | 12,607 |  |  |  | 13,744 |
Selling, general and administrative: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock-based compensation |  |  | 12,460 |  |  |  | 8,084 |  |  |  | 38,864 |  |  |  | 29,370 |
Loss on impairment of assets |  |  | 1,134 |  |  |  | - |  |  |  | 1,134 |  |  |  | 6,616 |
Changes in fair value of contingent consideration payable |  |  | 337 |  |  |  | 115 |  |  |  | 588 |  |  |  | (1,073 | )
Depreciation and amortization |  |  | 2,206 |  |  |  | 1,334 |  |  |  | 3,463 |  |  |  | 2,745 |
Total operating expense adjustments to reported GAAP |  |  | 20,254 |  |  |  | 13,912 |  |  |  | 56,656 |  |  |  | 51,402 |
Total operating expenses - as adjusted |  | $ | 83,995 |  |  | $ | 119,235 |  |  | $ | 164,557 |  |  | $ | 228,217 |

9